# iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. is a company headquartered in Watertown, MA, United States.

## Company overview

- **Legal name:** iTeos Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Watertown, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001808865

## About

iTeos Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001808865, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2025-03-05, it reported annual revenue of USD 35,000,000; net income of USD -134,414,000; total assets of USD 686,976,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $35.0M (USD 35,000,000)
- **Net income:** -$134.4M (USD -134,414,000)
- **Total assets:** $687.0M (USD 686,976,000)
- **Cash and equivalents:** $142.1M (USD 142,131,000)
- **Operating cash flow:** -$98.2M (USD -98,181,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $12.6M (USD 12,595,000)
- **Net income:** -$112.6M (USD -112,642,000)
- **Total assets:** $667.6M (USD 667,588,000)
- **Cash and equivalents:** $251.2M (USD 251,177,000)
- **Operating cash flow:** -$103.8M (USD -103,756,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $267.6M (USD 267,630,000)
- **Net income:** $96.7M (USD 96,652,000)
- **Total assets:** $755.0M (USD 754,991,000)
- **Cash and equivalents:** $284.8M (USD 284,803,000)
- **Operating cash flow:** -$111.2M (USD -111,193,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $344.8M (USD 344,775,000)
- **Net income:** $214.5M (USD 214,521,000)
- **Total assets:** $884.7M (USD 884,712,000)
- **Cash and equivalents:** $848.5M (USD 848,537,000)
- **Operating cash flow:** $513.1M (USD 513,140,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2025-08-29 — period 2025-08-29 — 8-K
- Form 10-Q — filed 2025-08-06 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-07-21 — period 2025-07-18 — 8-K
- Form 8-K — filed 2025-06-17 — period 2025-06-17 — 8-K
- Form 8-K — filed 2025-06-05 — period 2025-06-01 — 8-K
- Form 8-K — filed 2025-05-28 — period 2025-05-27 — 8-K
- Form 8-K — filed 2025-05-13 — period 2025-05-13 — 8-K
- Form 10-Q — filed 2025-04-28 — period 2025-03-31 — 10-Q
- Form DEF 14A — filed 2025-04-24 — period 2025-06-17 — DEF 14A
- Form 10-K — filed 2025-03-05 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-01-13 — period 2025-01-13 — 8-K
- Form SC 13G — filed 2024-11-21 — SCHEDULE 13G

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/iteos-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology